- Home
- CENN vs GDTC Comparison
CENN vs GDTC Comparison
Compare CENN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- GDTC
- Stock Information
- Founded
- CENN 2013
- GDTC 2018
- Country
- CENN United States
- GDTC Singapore
- Employees
- CENN N/A
- GDTC N/A
- Industry
- CENN Auto Manufacturing
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CENN Consumer Discretionary
- GDTC Health Care
- Exchange
- CENN Nasdaq
- GDTC Nasdaq
- Market Cap
- CENN 35.8M
- GDTC 33.4M
- IPO Year
- CENN N/A
- GDTC 2023
- Fundamental
- Price
- CENN $1.20
- GDTC $2.38
- Analyst Decision
- CENN
- GDTC Buy
- Analyst Count
- CENN 0
- GDTC 1
- Target Price
- CENN N/A
- GDTC $5.00
- AVG Volume (30 Days)
- CENN 193.1K
- GDTC 597.0K
- Earning Date
- CENN 02-12-2025
- GDTC 01-01-0001
- Dividend Yield
- CENN N/A
- GDTC N/A
- EPS Growth
- CENN N/A
- GDTC N/A
- EPS
- CENN N/A
- GDTC N/A
- Revenue
- CENN $37,052,841.00
- GDTC $330,254.00
- Revenue This Year
- CENN N/A
- GDTC $14.71
- Revenue Next Year
- CENN N/A
- GDTC N/A
- P/E Ratio
- CENN N/A
- GDTC N/A
- Revenue Growth
- CENN 142.48
- GDTC N/A
- 52 Week Low
- CENN $1.00
- GDTC $1.20
- 52 Week High
- CENN $2.30
- GDTC $4.30
- Technical
- Relative Strength Index (RSI)
- CENN 52.45
- GDTC 44.91
- Support Level
- CENN $1.13
- GDTC $2.12
- Resistance Level
- CENN $1.33
- GDTC $2.64
- Average True Range (ATR)
- CENN 0.08
- GDTC 0.48
- MACD
- CENN 0.01
- GDTC -0.10
- Stochastic Oscillator
- CENN 51.85
- GDTC 13.47
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.